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or nearly a century after the term “epigenetics”
first surfaced on the printed page, researchers,
physicians, and others poked around in the dark
crevices of the gene, trying to untangle the clues
that suggested gene function could be altered by
more than just changes in sequence. Today, a wide
variety of illnesses, behaviors, and other health
indicators already have some level of evidence
linking them with epigenetic mechanisms, includ-
ing cancers of almost all types, cognitive dysfunc-
tion, and respiratory, cardiovascular, reproductive,
autoimmune, and neurobehavioral illnesses. Known
or suspected drivers behind epigenetic processes
include many agents, including heavy metals,
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pesticides, diesel exhaust, tobacco smoke, poly-
cyclic aromatic hydrocarbons, hormones, radioac-
tivity, viruses, bacteria, and basic nutrients. 
In the past five years, and especially in the
past year or two, several groundbreaking studies
have focused fresh attention on epigenetics.
Interest has been enhanced as it has become clear
that understanding epigenetics and epigenomics—
the genomewide distribution of epigenetic
changes—will be essential in work related to many
other topics requiring a thorough understanding
of all aspects of genetics, such as stem cells,
cloning, aging, synthetic biology, species conser-
vation, evolution, and agriculture.
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Repression of transcription—the transfer of
genetic information from DNA to RNA—is
one route by which epigenetic mechanisms
can adversely impact health. 
Protein complexes, recruited to
methylated DNA, remove acetyl
groups and repress transcriptionMultiple Mechanisms
The word “epigenetic” literally means “in
addition to changes in genetic sequence.”
The term has evolved to include any
process that alters gene activity without
changing the DNA sequence, and leads to
modifications that can be transmitted to
daughter cells (although experiments show
that some epigenetic changes can be
reversed). There likely will continue to be
debate over exactly what the term means
and what it covers. 
Many types of epigenetic processes have
been identified—they include methylation,
acetylation, phosphorylation, ubiquityla-
tion, and sumolyation. Other epigenetic
mechanisms and considerations are likely
to surface as work proceeds. Epigenetic
processes are natural and essential to many
organism functions, but if they occur
improperly, there can be major adverse
health and behavioral effects.
Perhaps the best known epigenetic
process, in part because it has been easiest to
study with existing technology, is DNA
methylation. This is the addition or removal
of a methyl group (CH3), predominantly
where cytosine bases occur consecutively.
DNA methylation was first confirmed to
occur in human cancer in 1983, and has
since been observed in many other illnesses
and health conditions. 
Another significant epigenetic process
is chromatin modification. Chromatin is
the complex of proteins (histones) and
DNA that is tightly bundled to fit into the
nucleus. The complex can be modified by
substances such as acetyl groups (the
process called acetylation), enzymes, and
some forms of RNA such as microRNAs
and small interfering RNAs. This modifica-
tion alters chromatin structure to influence
gene expression. In general, tightly folded
chromatin tends to be shut down, or not
expressed, while more open chromatin is
functional, or expressed.
One effect of such processes is imprint-
ing. In genetics, imprinting describes the
condition where one of the two alleles of a
typical gene pair is silenced by an epigenet-
ic process such as methylation or acetyla-
tion. This becomes a problem if the
expressed allele is damaged or contains a
variant that increases the organism’s vulner-
ability to microbes, toxic agents, or other
harmful substances. Imprinting was first
identified in 1910 in corn, and first con-
firmed in mammals in 1991. 
Researchers have identified about 80
human genes that can be imprinted,
although that number is subject to debate
since the strength of the evidence varies.
That approximate number isn’t likely to
rise much in years to come, writes a team
including Ian Morison, a senior research
fellow in the Cancer Genetics Laboratory
at New Zealand’s University of Otago, in
the August 2005 Trends in Genetics. Others
in the field disagree. Randy Jirtle, a profes-
sor of radiation oncology at Duke Univ-
ersity Medical Center, and his colleagues
estimated in the June 2005 issue of
Genome Research that there could be about
600 imprinted genes in mice; in an
October 2005 interview Jirtle said he’s
anticipating a similar tally for humans,
even though the known imprintable genes
of mice and people have an overlap of only
about 35%. 
Links to Disease
Among all the epigenetics research con-
ducted so far, the most extensively studied
disease is cancer, and the evidence linking
epigenetic processes with cancer is becom-
ing “extremely compelling,” says Peter
Jones, director of the University of South-
ern California’s Norris Comprehensive
Cancer Center. Halfway around the
world, Toshikazu Ushijima is of the same
mind. The chief of the Carcinogenesis
Division of Japan’s National Cancer
Center Research Institute says epigenetic
mechanisms are one of the five most
important considerations in the cancer
field, and they account for one-third to
one-half of known genetic alterations. 
Many other health issues have drawn
attention. Epigenetic immune system
effects occur, and can be reversed, according to
research published in the November–
December 2005 issue of the Journal of
Proteome Research by Nilamadhab Mishra,
an assistant professor of rheumatology at
the Wake Forest University School of Med-
icine, and his colleagues. The team says it’s
the first to establish a specific link between
aberrant histone modification and mecha-
nisms underlying lupus-like symptoms in
mice, and they confirmed that a drug in
the research stage, trichostatin A, could
reverse the modifications. The drug
appears to reset the aberrant histone modi-
fication by correcting hypoacetylation at
two histone sites.
Lupus has also been a focus of Bruce
Richardson, chief of the Rheumatology
Section at the Ann Arbor Veterans Affairs
Medical Center and a professor at the
University of Michigan Medical School. In
studies published in the May–August 2004
issue of International Reviews of Im-
munology and the October 2003 issue
of  Clinical Immunology, he noted that
pharmaceuticals such as the heart drug pro-
cainamide and the antihypertensive agent
hydralazine cause lupus in some people,
and demonstrated that lupus-like disease in
mice exposed to these drugs is linked with
DNA methylation alterations and interrup-
tion of signaling pathways similar to those
in people.
Substantial Changes
Most epigenetic modification, by whatev-
er mechanism, is believed to be erased
with each new generation, during gameto-
genesis and after fertilization. However,
one of the more startling reports published
in 2005 challenges this belief and suggests
that epigenetic changes may endure in at
least four subsequent generations of
organisms. 
Michael Skinner, a professor of molecu-
lar biosciences and director of the Center
for Reproductive Biology at Washington
State University, and his team described in
the 3 June 2005 issue of Science how they
briefly exposed pregnant rats to individual
relatively high levels of the insecticide
methoxychlor and the fungicide vinclo-
zolin, and documented effects such as
decreased sperm production and increased
male infertility in the male pups. Digging
for more information, they found altered
DNA methylation of two genes. As they
continued the experiment, they discovered
the adverse effects lasted in about 90% of
the males in all four subsequent genera-
tions they followed, with no additional pes-
ticide exposures. 
The findings are not known to have
been reproduced. If they are reproducible,
however, it could “provide a new paradigm
for disease etiology and basic mechanisms
in toxicology and evolution not previously
appreciated,” says Skinner. He and his col-
leagues are conducting follow-up studies,
assessing many other genes and looking at
other effects such as breast and skin
tumors, kidney degeneration, and blood
defects. 
Other studies have found that epigenet-
ic effects occur not just in the womb, but
over the full course of a human life span.
Manel Esteller, director of the Cancer
Epigenetics Laboratory at the Spanish
National Cancer Center in Madrid, and his
colleagues evaluated 40 pairs of identical
twins, ranging in age from 3 to 74, and
found a striking trend, described in the
26 July 2005 issue of Proceedings of the
National Academy of Sciences. Younger twin
pairs and those who shared similar lifestyles
and spent more years together had very
similar DNA methylation and histone
acetylation patterns. But older twins, espe-
cially those who had different lifestyles
and had spent fewer years of their lives
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many different tissues, such as lymphocytes,
epithelial mouth cells, intra-abdominal fat,
and selected muscles. 
As one example, the researchers found
four times as many differentially expressed
genes between a pair of 50-year-old twins
compared to 3-year-old twins, and the 50-
year-old twin with more DNA hypo-
methylation and histone hyperacetylation
(the epigenetic changes usually associated
with transcriptional activity) had the high-
er number of overexpressed genes. The
degree of epigenetic change therefore was
directly linked with the degree of change
in genetic function.
Sometimes the effects of epigenetic
mechanisms show up in living color.
Changes in the pigmentation of mouse
pup fur, ranging from yellow to brown,
were directly tied to supplementation of
the pregnant mother’s diet with vitamin
B12, folic acid, choline, and betaine,
according to studies by Jirtle and Robert
Waterland published in August 2003 (issue
15) in Molecular and Cellular Biology. The
color changes were directly linked to alter-
ations in DNA methylation. In a study
forthcoming in the April 2006 issue of
EHP, Jirtle and his colleagues also induced
these alterations through maternal inges-
tion of genistein, the major phytoestrogen
in soy, at doses comparable to those a
human might receive from a high-soy diet.
The methylation changes furthermore
appeared to protect the mouse offspring
against obesity in adulthood, although
there are hints that genistein may also
cause health problems, via additive or syn-
ergistic effects on DNA methylation, when
it interacts with other substances such as
folic acid. 
Other Drivers of Change
Substances aren’t the only sources of epi-
genetic changes. The licking, grooming,
and nursing methods that mother rats use
with their pups can affect the long-term
behavior of their offspring, and those
results can be tied to changes in DNA
methylation and histone acetylation at a
glucocorticoid receptor gene promoter in
the pup’s hippocampus. This finding was
published in the August 2004 issue of
Nature Neuroscience by Moshe Szyf, a pro-
fessor in McGill University’s Department
of Pharmacology and Therapeutics, and
his colleagues. In the same study, the
researchers found that the effects weren’t
written in stone; giving the drug tricho-
statin A to older pups could help reverse
the effects of poor maternal care received
when they were younger. In the 6 June
2003 Journal of Biological Chemistry and
the 23 November 2005 Journal of
Neuroscience, Szyf and many of the same
colleagues also demonstrated that giving
the amino acid L-methionine to older
pups could negate the benefits of high-
quality maternal care received when they
were younger.
Along with behavior, mental health
may be affected by epigenetic changes, says
Arturas Petronis, head of the Krembil
Family Epigenetics Laboratory at the
Centre for Addiction and Mental Health in
Toronto. His lab is among the first in the
world, and still one of only a few, to study
links between epigenetics and psychiatry.
He and his colleagues are conducting large-
scale studies investigating links between
schizophrenia and aberrant methylation,
and he says understanding epigenetic
mechanisms is one of the highest priorities
in human disease biology research. “We
really need some radical revision of key
principles of the traditional genetic
research program,” he says. “Epigenetics
brings a new perspective on the old prob-
lem and new analytical tools that will help
to test the epigenetic theory.” He suggests
that more emphasis is needed on studying
non-Mendelian processes in diseases such
as schizophrenia, asthma, multiple sclero-
sis, and diabetes.
The past decade has also been produc-
tive in developing strong links between
aberrant DNA methylation and aging, says
Jean-Pierre Issa, a professor of medicine at
The University of Texas M.D. Anderson
Cancer Center. He presented information
on aging and epigenetic effects at a
November 2005 conference titled “Envi-
ronmental Epigenomics, Imprinting, and
Disease Susceptibility,” held in Durham,
North Carolina, and sponsored in part by
the NIEHS. Some of the strongest, decade-
old evidence shows progressive increases in
DNA methylation in aging colon tissues,
and more recent evidence links hyperme-
thylation with atherosclerosis. Altered, age-
related methylation has also been found in
tissues in the stomach, esophagus, liver,
kidney, and bladder, as well as the tissue
types studied by Esteller. Much of Issa’s
current work focuses on the links between
epigenetic processes, aging, the environ-
ment, and cancer, and possible ways to
therapeutically reverse methylation linked
with cancer.
Current and Future Quandaries 
The accumulated evidence indicates that
many genes, diseases, and environmental
substances are part of the epigenetics pic-
ture. However, the evidence is still far too
thin to form a basis for any overarching
theories about which substances and
which target genes are most likely to
mediate adverse effects of the environ-
ment on diseases, says Melanie Ehrlich, a
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A pup of a different color. Supplementation of maternal diet with genistein and other compounds
induced alterations in DNA methylation that were reflected in offspring coat color changes.Environmental Health Perspectives • VOLUME 114 | NUMBER 3 | March 2006 A 165
biochemistry professor at the Tulane
University School of Medicine and Tulane
Cancer Center who has been conducting
research on the topic for more than two
decades.
That sense of uncertainty generally
leaves epigenetics out of the regulatory pic-
ture. “It’s [too early] to actually use it at
the moment,” says Julian Preston, acting
associate director for health at the EPA’s
National Health and Environmental Ef-
fects Research Laboratory. But Preston says
the agency already relies more on its
improving understanding of mechanistic
processes, including epigenetics, and there
is a clear effort within the EPA to expand
genomics efforts both within the agency
and with others with whom the agency
works.
At the FDA, scientists are investigating
many drugs that function through epige-
netic mechanisms (although as spokes-
woman Christine Parker notes, the agency
bases its approvals on results of clinical tri-
als, not consideration of the mechanism by
which a drug works). One such drug, azac-
itidine, has been approved for use in the
United States to treat myelodysplastic syn-
drome, a blood disease that can progress to
leukemia. The drug turns on genes that
had been shut off by methylation. The
drug’s epigenetic function doesn’t make it a
“miracle drug,” however. Trials indicate it
benefits only 15% of those who take it,
and a high percentage of people suffer seri-
ous side effects, including nausea (71%),
anemia (70%), vomiting (54%), and fever
(52%). 
Ehrlich points out that azacitidine also
has effects at the molecular level—such as
inhibiting DNA replication and apopto-
sis—that may be part of its therapeutic
benefits. The drug’s mixed results might
also be explained in part by a study pub-
lished in the October 2004 issue of Cancer
Cell by Andrew Feinberg, director of the
Johns Hopkins University Center for
Epigenetics in Common Human Disease,
and his colleagues. They found that each of
two tested drugs, trichostatin A and 5-
aza-2´-deoxycytidine (which is related to
azacitidine), can turn on hundreds of genes
while also turning off hundreds of others.
If that finding holds in other studies, it
suggests one key reason why it is so diffi-
cult to create a drug that doesn’t cause
unintended side effects.
Public and Private
Despite the potentially huge role that epi-
genetics may play in human disease, invest-
ment in this area of study remains tiny
compared to that devoted to traditional
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n December 2005 a group of 40
international scientists publicly
proposed a U.S. Human Epigen-
ome Project to complement a
European project of the same
name launched in 2003. Group
member Andrew Feinberg, a
geneticist at the Johns Hopkins
University School of
Medicine, says, “We’re
hoping to see how this
idea takes hold. There
is this ocean of infor-
mation that is largely
unexplored.”
The goal of the
U.S. project will be to
comprehensively map
methylation and his-
tone modifications
—the two main class-
es of epigenetic mod-
ifications—in a diverse
set of normal tissues.
These epigenomes
would then serve as
a reference for com-
parison with diseased
tissues, revealing epi-
genetic causes of dis-
ease. Project organizers are now
compiling a detailed proposal, with
budget estimates and a timeline.
Although both the U.S. and
European projects ultimately aim
to map all genes, the U.S. effort
will look at different tissue and
cell types than the European
effort, and will also look at model
organisms like yeast and the fly.
The two groups are already work-
ing closely together in planning
their projects to avoid redundan-
cies, and this cooperation will
likely continue.
Understanding cancer would
be one long-term goal for the U.S.
project, but epigenetics—changes
in gene expression heritable from
cell to daughter cell without
changes in DNA sequence—tran-
scends any one disease. “It has
profound implications in aging,
neurological disorders,
and child develop-
ment,” says Peter
Jones, another group
member and director
of the Norris Compre-
hensive Cancer Center
at the University of
Southern California.
Jones and his col-
leagues argue that
the importance of epi-
genetics in human dis-
ease, together with
the maturing of tech-
nologies for mapping
epigenetic changes,
make a human epi-
genome project both
critical and feasible.
Epigenetics, says
cancer biologist Jean-
Pierre Issa of The University of
Texas M.D. Anderson Cancer Center,
could prove more important than
genetics for understanding envi-
ronmental causes of disease.
“Cancer, atherosclerosis, Alzheim-
er’s disease [are all] acquired dis-
eases where the environment very
likely plays an important role,” he
points out. “And there’s much
more potential for the epi-
genome to be affected . . . than
the genome itself. It’s just more
fluid and more easy to be the cul-
prit.” – Ken Garber
U.S. Human Epigenome Projectgenetics work. Several efforts to change
that are under way. 
In Europe, the Human Epigenome
Project was officially launched in 2003 by
the Wellcome Trust Sanger Institute,
Epigenomics AG, and the Centre National
de Génotypage. The group’s focus is on
DNA methylation research tied to chro-
mosomes 6, 13, 20, and 22. They may be
joined soon by organizations in Germany
and India, where scientists plan to work on
chromosomes 21 and X, respectively, says
Sanger senior investigator Stephan Beck. 
But comprehensively studying all the
epigenetic and epigenomic factors related
to a multitude of diseases and health con-
ditions will take much more work. “A
[comprehensive] Human Epigenome
Project is a lot more complicated than a
Human Genome Project,” Jones says.
“There’s only one genome, [but] an epi-
genome varies in each and every tissue.”
The Human Genome Project was a world-
wide effort that took more than a decade
and billions of dollars to complete.
Jones and Robert Martienssen ad-
dressed some of the complexities of a com-
prehensive, worldwide Human Epigenome
Project in the 15 December 2005 issue of
Cancer Research. Reporting on a June 2005
workshop convened by the American
Association for Cancer Research, they con-
cluded that, despite all the looming diffi-
culties, such a project is essential, and the
technology is sufficiently advanced to
begin. 
“I think it’s going to happen a lot soon-
er than I thought just a year or so ago,” Jirtle
says. A group of researchers has already start-
ed the footwork to launch a U.S. comple-
ment to the European Human Epigenome
Project effort [see box, p. A165]. 
Other efforts are gaining ground.
Another European group, the Epigenome
Network of Excellence, took off in June
2004. This information exchange network
includes members in the public and pri-
vate sectors spread throughout ten Western
European countries. Their objectives are to
coordinate research, provide mentors, and
encourage dialogue via their website. And
in Asia, a conference held 7–10 November
2005 in Tokyo, “Genome-Wide Epigen-
etics 2005,” was dedicated in large part to
facilitating a coordinated epigenomics
research effort in Japan and possibly all of
Asia, says Ushijima, one of the conference’s
organizers. 
In the United States, the National
Cancer Institute and the National Human
Genome Research Institute formally kicked
off a major effort 13 December 2005 that
will include epigenomic work. The pilot
project of The Cancer Genome Atlas, fund-
ed by $50 million each from the two insti-
tutes, is designed to lay the groundwork for
comprehensive study of genomic factors
related to human cancer. The initial three-
year effort is expected to focus on just two
or three of the more than 200 cancers
known to exist, but if it’s successful in
developing methods and technologies, the
number of cancers evaluated could then
expand. If a high number of cancer genes
are eventually scrutinized, the effort would
be the equivalent of thousands of Human
Genome Projects. 
To help push the boundaries further, the
NIEHS and the National Cancer Institute
are in the midst of awarding grants totaling
$3.75 million to study a wide range of epi-
genetic topics, such as identification of
high-risk populations, dietary influences
on cancer, and detailed study of numerous
specific mechanisms linking environmental
agents with epigenetic mechanisms and
resulting disease. The dozen or so recipi-
ents are expected to launch their projects
by fall 2006.
The NIEHS has also begun to integrate
epigenomics projects into its research port-
folio over the past five to six years. “It’s an
emerging area that’s very important,” says
Frederick Tyson, a program administrator
in the NIEHS Division of Extramural
Research and Training. And epigenetics is
likely to be one of the half dozen or so most
important considerations as NIEHS pro-
ceeds with its Environmental Genome
Project, according to institute director
David Schwartz.
The DNA Methylation Society, a pro-
fessional group, has been growing slowly
but steadily over the past decade, says
founder and current vice president Ehrlich.
As part of its efforts, the society launched a
journal, Epigenetics, in January 2006 with
the goal of covering a full spectrum of epi-
genetic considerations—medical, nutri-
tional, psychological, behavioral—in any
organism. Such groups are a valuable rally-
ing point for this field, Jirtle says. He him-
self slowly worked his way into epigenetics
from an initial cancer focus, and his segue
is typical of many. “If you study epigenet-
ics, you don’t have a home; we come from
all different fields,” he says. 
Interest in the private sector is also pick-
ing up. For instance, Epigenomics AG, with
offices in Berlin and Seattle, is working on
early detection and diagnosis of cancer and
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Professional Organizations and Projects
• DNA Methylation Society (international) 
http://www.dnamethsoc.com/main.htm 
• Epigenome Network of Excellence (Europe) 
http://www.epigenome-noe.net
• Human Epigenome Project (Europe)
http://www.epigenome.org 
Journal
Epigenetics
http://www.landesbioscience.com/journals/epigenetics/
DNA Methylation Database
http://www.methdb.de/front.html
Imprinted Gene Databases
• http://igc.otago.ac.nz/home.html 
• http://www.geneimprint.com/databases/?c=clist 
• http://www.mgu.har.mrc.ac.uk/research/imprinting/
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endometriosis (for which there is limited
evidence of an epigenetic component), as
well as development of products to predict
effectiveness of drugs to treat these diseases.
Founded in 1998, and now with about 150
employees, the company is focusing on
DNA methylation mechanisms, and is
working with companies such as Abbott
Laboratories, Johnson & Johnson, Philip
Morris, Roche Diagnostics, Pfizer, and
AstraZeneca. CEO Oliver Schacht says the
surging interest in this field is typified by
the difference between the 2004 American
Association for Cancer Research confer-
ence, which had half a dozen or so talks or
posters on epigenetics, and the 2005 event,
which had about 200. 
Tool Time
If epigenetic work is to continue breaking
new ground, many observers say technolo-
gy will need to continue advancing. Jones
and Martienssen note in their paper that
there must be additional improvements in
high-throughput technologies, analytical
techniques, computational capability,
mechanistic studies, and bioinformatic
strategies. They also say there is a need for
basics such as standardized reagents and a
consistent supply of antibodies for testing. 
Preston agrees with many of these ideas,
and says there is also a need to develop a
comprehensive tally of all proteins in the
cell and to get better protein modification
information. He says universities are recog-
nizing the demand for the talents needed to
solve epigenomics problems, and are
increasing their efforts to cover these topics
in various ways, especially at the graduate
school level.
Other groups are doing their part by
creating tools to further the field. All the
imprinted genes identified so far are tracked
in complementary efforts by Morison’s and
Jirtle’s groups and the Mammalian Genetics
Unit of the U.K. Medical Research Coun-
cil. The European managers of the DNA
Methylation Database have assembled a
compendium of known DNA methylations
that, although not comprehensive, still pro-
vides a useful tool for researchers investigat-
ing the roughly 22,000 human genes. 
Kunio Shiota, a professor of cellular
biochemistry at the University of Tokyo
and one of the co-organizers of the
November 2005 Tokyo conference, says
epigenetic advances will rely in part on a
range of processes that are slowly becoming
familiar to more researchers—massively
parallel signature sequencing (MPSS),
chromatin immunoprecipitation microar-
ray analysis (ChIP-chip), DNA adenine
methyltransferase identification (Dam-ID),
protein binding microarrays (PBM), DNA
immunoprecipitation microarray analysis
(DIP-chip), and more. Someday, he says,
these terms could become fully as familiar
as MRI and EKG.
The rapidly growing acceptance of epi-
genetics, a century after it first surfaced, is
a huge step forward, in Jirtle’s opinion.
“We’ve done virtually nothing so far,” he
says. “I’m biased, but the tip of the iceberg
is genomics and single-nucleotide poly-
morphisms. The bottom of the iceberg is
epigenetics.”
Bob Weinhold
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